Trial Profile
A Study Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2014
Price :
$35
*
At a glance
- Drugs Travoprost/verosudil (Primary) ; Travoprost; Verosudil
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Aerie Pharmaceuticals
- 09 Apr 2014 New trial record